LV13000B - Venlafaxine and its analogues for inducing cognition enhancement - Google Patents
Venlafaxine and its analogues for inducing cognition enhancement Download PDFInfo
- Publication number
- LV13000B LV13000B LVP-03-34A LV030034A LV13000B LV 13000 B LV13000 B LV 13000B LV 030034 A LV030034 A LV 030034A LV 13000 B LV13000 B LV 13000B
- Authority
- LV
- Latvia
- Prior art keywords
- carbon atoms
- alkyl
- use according
- hydrogen
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Carbon And Carbon Compounds (AREA)
- Traffic Control Systems (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
- LV 13000 FORMULA 1. Savienojuma ar formulu:, kur A ir grupa ar formulu: or4 \ ) (CH2)n , kur raustītā līnija apzīmē iespējamu nepiesātinātību; Rļ ir ūdeņraža atoms vai alkilgrupa ar 1 līdz 6 oglekļa atomiem; R2 ir alkilgrupa ar 1 fīdz 6 oglekļa atomiem; R4 ir ūdeņraža atoms, alkilgrupa ar 1 līdz 6 oglekļa atomiem, formilgrupa, vai alkanoilgrupa ar 2 līdz 7 oglekļa atomiem; R5 un R6 neatkarīgi viens no otra ir ūdeņraža atoms, hidroksilgrupa, alkilgrupa ar 1 līdz 6 oglekļa atomiem, alkoksigrupa ar 1 līdz 6 oglekļa atomiem, alkanoiloksigrupa ar 2 līdz 7 oglekļa atomiem, cianogrupa, nitrogrupa, alkilmerkaptogrupa ar 1 līdz 6 oglekļa atomiem, aminogrupa, alkilaminogrupa ar 1 līdz 6 oglekļa atomiem, dialkilaminogrupa, kur katra alkilgrupa satur 1 līdz 6 oglekļa atomus, alkānamidogrupa ar 2 līdz 7 oglekļa atomiem, halogēns, trifluorometilgrupa, vai arī kopā, metilēndioksigrupa; R7 ir ūdeņraža atoms vai alkilgrupa ar 1 līdz 6 oglekļa atomiem; un n ir 0,1, 2, 3, vai 4; vai tā farmaceitiski pieņemamas sāls lietošana, lai izgatavotu medikamentus kognitīvo traucējumu ārstēšanai zīdītājos, kur kognitīvo traucējumu iemesls ir plānprātība.
- 2. Lietošana saskaņā ar punktu 1, kur savienojums ir savienojums ar formulu: 2, kur A ir kā definēts punktā 1; Ri ir ūdeņraža atoms vai alkilgrupa ar 1 līdz 3 oglekļa atomiem; R2 ir alkilgrupa ar 1 līdz 3 oglekļa atomiem; R5 ir ūdeņraža atoms, hidroksilgrupa, alkoksigrupa ar 1 līdz 3 oglekļa atomiem, hlors, broms, trifluorometilgrupa vai alkilgrupa ar 1 līdz 3 oglekļa atomiem; R6 ir alkilgrupa ar 1 līdz 3 oglekļa atomiem, alkoksigrupa ar 1 līdz 3 oglekļa atomiem, hlors, broms, trifluorometilgrupa vai alkanoiloksigrupa ar 2 līdz 3 oglekļa atomiem; un R7 ir ūdeņraža atoms vai alkilgrupa ar 1 līdz 3 oglekļa atomiem vai tā farmaceitiski pieņemama sāls.
- 3. Lietošana saskaņā ar punktiem 1 vai 2, kur R5 un R6 atrodas meta stāvokļos vai viens no R5 vai R6 atrodas para stāvoklī, un n ir 2.
- 4. Lietošana saskaņā ar punktiem 1 vai 2, kur savienojums ir 1-[(2-dimetilamino)-1-(4-metoksifenil)etil]cikloheksanols vai tā farmaceitiski pieņemama sāls.
- 5. Lietošana saskaņā ar punktiem 1 vai 2, kur savienojums ir 1-[(2-dimetilamino)-1-(4-hidroksifenil)etil]cikloheksanols vai tā farmaceitiski pieņemama sāls.
- 6. Lietošana saskaņā ar jebkuru no iepriekšējiem punktiem, kur medikaments ir paredzēts cilvēka uztveres spēju uzlabošanas stimulēšanai.
- 7. Lietošana saskaņā ar jebkuru no iepriekšējiem punktiem, kur kognitīvos traucējumus izraisījusi Alcheimera tipa plānprātība.
- 8. Lietošana saskaņā ar jebkuru no punktiem 1 līdz 6, kur kognitīvos traucējumus izraisījusi Parkinsona slimība. 3 LV 13000
- 9. Lietošana saskaņā ar jebkuru no punktiem 1 līdz 6, kur kognitīvos traucējumus izraisījuši ar vecumu saistītie atmiņas traucējumi.
- 10. Lietošana saskaņā ar jebkuru no iepriekšējiem punktiem, kur minētā savienojuma 5 dienas doza atrodas robežās no 50 mg/dienā līdz 375 mg/dienā.
- 11. Lietošana saskaņā ar punktu 10, kur minētā savienojuma dienas doza ir 75 mg/dienā līdz 200 mg/dienā.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19541794A | 1994-02-14 | 1994-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LV13000B true LV13000B (en) | 2003-07-20 |
Family
ID=22721346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-03-34A LV13000B (en) | 1994-02-14 | 2003-03-17 | Venlafaxine and its analogues for inducing cognition enhancement |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP0667150B1 (lv) |
| JP (1) | JPH07252143A (lv) |
| AT (1) | ATE229328T1 (lv) |
| CA (1) | CA2141774A1 (lv) |
| CY (1) | CY2321B1 (lv) |
| DE (1) | DE69529109T2 (lv) |
| DK (1) | DK0667150T3 (lv) |
| ES (1) | ES2185683T3 (lv) |
| LV (1) | LV13000B (lv) |
| PT (1) | PT667150E (lv) |
| SG (1) | SG49680A1 (lv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| ES2305606T3 (es) | 1999-04-06 | 2008-11-01 | Sepracor Inc. | Succinato de o-desmetilvenlafaxina. |
| EP1360169B2 (en) * | 2001-02-12 | 2017-05-24 | Wyeth LLC | Succinate salt of o-desmethyl-venlafaxine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| PT1738753E (pt) * | 1993-06-28 | 2008-06-19 | Wyeth Corp | Novos tratamentos utilizando derivados de fenetilamina |
-
1995
- 1995-01-31 PT PT95300612T patent/PT667150E/pt unknown
- 1995-01-31 DK DK95300612T patent/DK0667150T3/da active
- 1995-01-31 AT AT95300612T patent/ATE229328T1/de not_active IP Right Cessation
- 1995-01-31 ES ES95300612T patent/ES2185683T3/es not_active Expired - Lifetime
- 1995-01-31 DE DE69529109T patent/DE69529109T2/de not_active Expired - Fee Related
- 1995-01-31 EP EP95300612A patent/EP0667150B1/en not_active Expired - Lifetime
- 1995-01-31 EP EP02014620A patent/EP1245228A3/en not_active Withdrawn
- 1995-01-31 SG SG1996004003A patent/SG49680A1/en unknown
- 1995-02-03 CA CA002141774A patent/CA2141774A1/en not_active Abandoned
- 1995-02-13 JP JP7023837A patent/JPH07252143A/ja not_active Withdrawn
-
2003
- 2003-03-17 LV LVP-03-34A patent/LV13000B/en unknown
- 2003-03-24 CY CY0300031A patent/CY2321B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2141774A1 (en) | 1995-08-15 |
| PT667150E (pt) | 2003-02-28 |
| EP1245228A3 (en) | 2002-10-09 |
| SG49680A1 (en) | 1998-06-15 |
| ES2185683T3 (es) | 2003-05-01 |
| DE69529109D1 (de) | 2003-01-23 |
| EP0667150B1 (en) | 2002-12-11 |
| DK0667150T3 (da) | 2003-03-31 |
| DE69529109T2 (de) | 2003-04-30 |
| CY2321B1 (en) | 2003-11-14 |
| EP0667150A1 (en) | 1995-08-16 |
| JPH07252143A (ja) | 1995-10-03 |
| ATE229328T1 (de) | 2002-12-15 |
| EP1245228A2 (en) | 2002-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5530013A (en) | Venlafaxine in the inducement of cognition enhancement | |
| US6287597B1 (en) | Antihistaminic/decongestant compositions | |
| AU727851B2 (en) | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| LV12881B (lv) | Jaunas ārstēšanas metodes, izmantojot fenetilatvasinājumus | |
| US6306904B1 (en) | Antihistaminic/antitussive compositions | |
| US6037358A (en) | Decongestant/antihistaminic compositions | |
| US6417206B1 (en) | Antitussive/antihist aminic/decongestant compositions | |
| CA2227208A1 (en) | Pharmaceutical composition of l-dopa ethyl ester | |
| CZ20024110A3 (cs) | Léčivo pro léčení poruch spánku | |
| US20040034101A1 (en) | Treatment and prevention of depression secondary to pain (DSP) | |
| AU2003232137A1 (en) | Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives | |
| US5656669A (en) | Restorative neuropharmacological agent for motor and speech disturbance | |
| LV13000B (en) | Venlafaxine and its analogues for inducing cognition enhancement | |
| WO2004089351A2 (en) | Treatment of progressive neurological disorders comprising a mao inhibitor (miclobemid) and an acetylcholinesterase inhibitor (tacrin) | |
| Aminoff | Basic & Clinical Pharmacology | |
| US20010011104A1 (en) | Antihistamine compositions | |
| US6586469B2 (en) | Antihistaminic/antitussive compositions | |
| US3961073A (en) | Antidepressant | |
| IL122853A (en) | Use of allylamines in the preparation of pharmaceutical preparations | |
| WO2001034140A1 (en) | Pharmaceutical formulation | |
| US3772440A (en) | Method for the treatment of parkinsonism and depression | |
| IE76322B1 (en) | Use of phenylethanolaminotetralines for preparing antidepressant and anti-stress medicines | |
| CA2493490A1 (en) | Treatment of depression secondary to pain (dsp) | |
| AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
| US3755567A (en) | Method for treating alcoholism |